985 clinical efficacy and pharmacokinetics (pk) of moxalactam (mlm) in pediatric skeletal infections

985 clinical efficacy and pharmacokinetics (pk) of moxalactam (mlm) in pediatric skeletal infections

Play all audios:

Loading...

ABSTRACT The clinical efficacy and PK of the new β-lactam antibiotic, MLM, was investigated in 8 pediatric patients (8 wks.-16 yrs.) with skeletal infections. All patients received 150 mg/k/day IV in 3 divided doses for 1-4 weeks. Five children had osteomyelitis 3 with S. aureus, 1 with Serratia spp., and 1 with K. pneumoniae. Two had purulent synovial fluid without recovery of an organism. One had both osteomyelitis and septic arthritis due to S. aureus. All children demonstrated clinical improvement within 48 hrs. of the initiation of therapy. No drug-related toxicity was noted. In all cases, cultures at the termination of therapy were sterile. Ultimately, all had normal musculoskeletal function. After the initial dose and again after 3-5 days of therapy the PK of MLM were determined. A new, HPLC technique was used to measure serum concentrations. No difference in PK parameters was observed at the two time intervals. Mean peak serum concentrations were 235±48 μg/ml and exceeded the MIC's of the separate organisms for at least 3 hrs. No drug accumulation occurred during continuous therapy. The t½β was 100±31 min. and was independent of patient age. The apparent volume of distribution was ∼0.45 L/kg suggesting good tissue penetration. We conclude that MLM is a safe, effective antimicrobial agent for the treatment of skeletal infections in childhood. ARTICLE PDF AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Departments of Pediatrics and Orthopaedics, Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland Stephen C Aronoff, Peter V Scoles, Michael D Reed, Carolyn Meyers, Joseph S Bertino, Jeffrey L Blumer & W T Speck Authors * Stephen C Aronoff View author publications You can also search for this author inPubMed Google Scholar * Peter V Scoles View author publications You can also search for this author inPubMed Google Scholar * Michael D Reed View author publications You can also search for this author inPubMed Google Scholar * Carolyn Meyers View author publications You can also search for this author inPubMed Google Scholar * Joseph S Bertino View author publications You can also search for this author inPubMed Google Scholar * Jeffrey L Blumer View author publications You can also search for this author inPubMed Google Scholar * W T Speck View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Aronoff, S., Scoles, P., Reed, M. _et al._ 985 CLINICAL EFFICACY AND PHARMACOKINETICS (PK) OF MOXALACTAM (MLM) IN PEDIATRIC SKELETAL INFECTIONS. _Pediatr Res_ 15 (Suppl 4), 606 (1981). https://doi.org/10.1203/00006450-198104001-01010 Download citation * Issue Date: 01 April 1981 * DOI: https://doi.org/10.1203/00006450-198104001-01010 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative

ABSTRACT The clinical efficacy and PK of the new β-lactam antibiotic, MLM, was investigated in 8 pediatric patients (8 wks.-16 yrs.) with skeletal infections. All patients received 150


mg/k/day IV in 3 divided doses for 1-4 weeks. Five children had osteomyelitis 3 with S. aureus, 1 with Serratia spp., and 1 with K. pneumoniae. Two had purulent synovial fluid without


recovery of an organism. One had both osteomyelitis and septic arthritis due to S. aureus. All children demonstrated clinical improvement within 48 hrs. of the initiation of therapy. No


drug-related toxicity was noted. In all cases, cultures at the termination of therapy were sterile. Ultimately, all had normal musculoskeletal function. After the initial dose and again


after 3-5 days of therapy the PK of MLM were determined. A new, HPLC technique was used to measure serum concentrations. No difference in PK parameters was observed at the two time


intervals. Mean peak serum concentrations were 235±48 μg/ml and exceeded the MIC's of the separate organisms for at least 3 hrs. No drug accumulation occurred during continuous therapy.


The t½β was 100±31 min. and was independent of patient age. The apparent volume of distribution was ∼0.45 L/kg suggesting good tissue penetration. We conclude that MLM is a safe, effective


antimicrobial agent for the treatment of skeletal infections in childhood. ARTICLE PDF AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Departments of Pediatrics and Orthopaedics, Case Western


Reserve University, Rainbow Babies and Children's Hospital, Cleveland Stephen C Aronoff, Peter V Scoles, Michael D Reed, Carolyn Meyers, Joseph S Bertino, Jeffrey L Blumer & W T


Speck Authors * Stephen C Aronoff View author publications You can also search for this author inPubMed Google Scholar * Peter V Scoles View author publications You can also search for this


author inPubMed Google Scholar * Michael D Reed View author publications You can also search for this author inPubMed Google Scholar * Carolyn Meyers View author publications You can also


search for this author inPubMed Google Scholar * Joseph S Bertino View author publications You can also search for this author inPubMed Google Scholar * Jeffrey L Blumer View author


publications You can also search for this author inPubMed Google Scholar * W T Speck View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND


PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Aronoff, S., Scoles, P., Reed, M. _et al._ 985 CLINICAL EFFICACY AND PHARMACOKINETICS (PK) OF MOXALACTAM (MLM) IN


PEDIATRIC SKELETAL INFECTIONS. _Pediatr Res_ 15 (Suppl 4), 606 (1981). https://doi.org/10.1203/00006450-198104001-01010 Download citation * Issue Date: 01 April 1981 * DOI:


https://doi.org/10.1203/00006450-198104001-01010 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is


not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative